$NMRD
Nemaura Medical Inc. Stock $nmrd

$nmrd Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000107997323001137 Filed on August 14, 2023

Income Statement

Concept	2023 Q2	2022 Q2
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue	$0.00	$0.00
YoY Change
Gross Profit	$0.00	$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.508M	$1.881M
YoY Change	-19.8%	41.19%
% of Gross Profit
Research & Development	$549.8K	$330.1K
YoY Change	66.57%	14.41%
% of Gross Profit
Depreciation & Amortization	$98.09K	$98.79K
YoY Change	-0.72%	173.41%
% of Gross Profit
Operating Expenses	$2.058M	$2.211M
YoY Change	-6.91%	36.42%
Operating Profit	-$1.834M	-$2.211M
YoY Change	-17.04%	36.42%
Interest Expense	-$432.9K	-$1.768M
YoY Change	-75.52%	2.63%
% of Operating Profit
Other Income/Expense, Net	-$112.0K	$0.00
YoY Change
Pretax Income	-$2.603M	-$3.979M
YoY Change	-34.58%	19.01%
Income Tax
% Of Pretax Income
Net Earnings	-$2.603M	-$3.979M
YoY Change	-34.58%	19.01%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.09	-$0.16
Diluted Earnings Per Share	-$0.09	-$165.1K
COMMON SHARES
Basic Shares Outstanding	28.90M shares	24.10M shares
Diluted Shares Outstanding	28.90M shares	24.10M shares

Balance Sheet

Concept	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.010M	$14.75M
YoY Change	-72.82%	-52.81%
Cash & Equivalents	$4.010M	$14.75M
Short-Term Investments
Other Short-Term Assets	$857.7K	$1.106M
YoY Change	-22.41%	-39.25%
Inventory	$2.351M	$1.625M
Prepaid Expenses
Receivables		$217.5K
Other Receivables		$0.00
Total Short-Term Assets	$7.473M	$17.70M
YoY Change	-57.78%	-48.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$629.0K	$603.1K
YoY Change	4.29%	135.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$2.015M
YoY Change
Total Long-Term Assets	$977.2K	$2.015M
YoY Change	-51.5%	24.91%
TOTAL ASSETS
Total Short-Term Assets	$7.473M	$17.70M
Total Long-Term Assets	$977.2K	$2.015M
Total Assets	$8.450M	$19.72M
YoY Change	-57.14%	-44.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$257.0K	$92.70K
YoY Change	177.18%	-14.01%
Accrued Expenses	$253.2K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$16.97M	$16.19M
YoY Change	4.83%	45.26%
Total Short-Term Liabilities	$21.65M	$17.95M
YoY Change	20.65%	44.48%
LONG-TERM LIABILITIES
Long-Term Debt	$119.5K	$4.700M
YoY Change	-97.46%	-66.49%
Other Long-Term Liabilities	$1.054M	$1.025M
YoY Change	2.8%	-19.07%
Total Long-Term Liabilities	$119.5K	$5.725M
YoY Change	-97.91%	-62.56%
TOTAL LIABILITIES
Total Short-Term Liabilities	$21.65M	$17.95M
Total Long-Term Liabilities	$119.5K	$5.725M
Total Liabilities	$22.83M	$23.67M
YoY Change	-3.57%	-14.58%
SHAREHOLDERS EQUITY
Retained Earnings	-$54.48M	-$41.71M
YoY Change	30.61%
Common Stock	$41.02M	$38.32M
YoY Change	7.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$14.38M	-$3.958M
YoY Change
Total Liabilities & Shareholders Equity	$8.450M	$19.72M
YoY Change	-57.14%	-44.75%

Cashflow Statement

Concept	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$2.603M	-$3.979M
YoY Change	-34.58%	19.01%
Depreciation, Depletion And Amortization	$98.09K	$98.79K
YoY Change	-0.72%	173.41%
Cash From Operating Activities	-$2.521M	-$2.384M
YoY Change	5.75%	41.07%
INVESTING ACTIVITIES
Capital Expenditures	$29.21K	$25.60K
YoY Change	14.09%	-68.87%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$29.21K	-$217.7K
YoY Change	-86.59%	-45.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$3.600M	-$74.28K
YoY Change	4746.4%	-105.08%
NET CHANGE
Cash From Operating Activities	-$2.521M	-$2.384M
Cash From Investing Activities	-$29.21K	-$217.7K
Cash From Financing Activities	-$3.600M	-$74.28K
Net Change In Cash	-$6.151M	-$2.676M
YoY Change	129.83%	328.46%
FREE CASH FLOW
Cash From Operating Activities	-$2.521M	-$2.384M
Capital Expenditures	$29.21K	$25.60K
Free Cash Flow	-$2.551M	-$2.410M
YoY Change	5.84%	35.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	dei	Entity Central Index Key EntityCentralIndexKey	0001602078
CY2023Q2	dei	Amendment Flag AmendmentFlag	false
CY2023Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2023Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	dei	Document Type DocumentType	10-Q
CY2023Q2	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q2	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
CY2023Q2	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q2	dei	Entity File Number EntityFileNumber	001-38355
CY2023Q2	dei	Entity Registrant Name EntityRegistrantName	Nemaura Medical Inc.
CY2023Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-5027260
CY2023Q2	dei	Entity Address Address Line1 EntityAddressAddressLine1	57 West 57th Street
CY2023Q2	dei	Entity Address City Or Town EntityAddressCityOrTown	Manhattan
CY2023Q2	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023Q2	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10019
CY2023Q2	dei	City Area Code CityAreaCode	646
CY2023Q2	dei	Local Phone Number LocalPhoneNumber	416-8000
CY2023Q2	dei	Security12b Title Security12bTitle	Common Stock
CY2023Q2	dei	Trading Symbol TradingSymbol	NMRD
CY2023Q2	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q2	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q2	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q2	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28899402	shares
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4009691	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10105135	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2351286	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	1754852	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	467016	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	357934	usd
CY2023Q2	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	254106	usd
CY2023Q1	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	409648	usd
CY2023Q2	nmrd	Deposit On Foreign Exchange Contract DepositOnForeignExchangeContract	390713	usd
CY2023Q1	nmrd	Deposit On Foreign Exchange Contract DepositOnForeignExchangeContract	909666	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	7472812	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	13537235	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	629007	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	641906	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	348214	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	384092	usd
CY2023Q2	us-gaap	Assets Assets	8450033	usd
CY2023Q1	us-gaap	Assets Assets	14563233	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	256950	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	326641	usd
CY2023Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	253246	usd
CY2023Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	130678	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	16967686	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	16942500	usd
CY2023Q2	nmrd	Payable To Related Parties PayableToRelatedParties	337735	usd
CY2023Q1	nmrd	Payable To Related Parties PayableToRelatedParties	920780	usd
CY2023Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	127140	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	123640	usd
CY2023Q2	nmrd	Foreign Exchange Contract Derivative Liability ForeignExchangeContractDerivativeLiability	507648	usd
CY2023Q1	nmrd	Foreign Exchange Contract Derivative Liability ForeignExchangeContractDerivativeLiability	731730	usd
CY2023Q2	nmrd	Warrant Liability WarrantLiability	3204000	usd
CY2023Q1	nmrd	Warrant Liability WarrantLiability	3092000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	21654405	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	22267969	usd
CY2023Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	119477	usd
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	3087651	usd
CY2023Q2	us-gaap	Deferred Revenue And Credits Noncurrent DeferredRevenueAndCreditsNoncurrent	1053915	usd
CY2023Q1	us-gaap	Deferred Revenue And Credits Noncurrent DeferredRevenueAndCreditsNoncurrent	1021811	usd
CY2023Q2	us-gaap	Liabilities Liabilities	22827797	usd
CY2023Q1	us-gaap	Liabilities Liabilities	26377431	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	42000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	42000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28899402	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28899402	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28899402	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28899402	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	28899	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	28899	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	40991377	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	40991377	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-54478365	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-51875211	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-919675	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-959263	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-14377764	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-11814198	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8450033	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14563233	usd
CY2023Q2	us-gaap	Revenues Revenues	0	usd
CY2022Q2	us-gaap	Revenues Revenues	0	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	-0	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	-0	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	0	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	0	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	549757	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	330055	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1508467	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1267251	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	2058224	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	1597306	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1834142	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2436890	usd
CY2023Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-657012	usd
CY2022Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1452020	usd
CY2023Q2	nmrd	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-112000	usd
CY2022Q2	nmrd	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	0	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2603154	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3888910	usd
CY2023Q2	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	39588	usd
CY2022Q2	us-gaap	Translation Adjustment Functional To Reporting Currency Increase Decrease Gross Of Tax TranslationAdjustmentFunctionalToReportingCurrencyIncreaseDecreaseGrossOfTax	-444937	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2563566	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4333847	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28899402	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28899402	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24102866	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24102866	shares
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-11814198	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	39588	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2603154	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-14377764	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	466084	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	-444937	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3888910	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3867763	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2603154	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3888910	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	98085	usd
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	98792	usd
CY2023Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	164375	usd
CY2022Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2023Q2	us-gaap	Paid In Kind Interest PaidInKindInterest	492637	usd
CY2022Q2	us-gaap	Paid In Kind Interest PaidInKindInterest	0	usd
CY2023Q2	us-gaap	Accretion Expense AccretionExpense	0	usd
CY2022Q2	us-gaap	Accretion Expense AccretionExpense	1452020	usd
CY2023Q2	nmrd	Change In Fair Value Of Foreign Exchange Contract ChangeInFairValueOfForeignExchangeContract	-224082	usd
CY2022Q2	nmrd	Change In Fair Value Of Foreign Exchange Contract ChangeInFairValueOfForeignExchangeContract	839584	usd
CY2023Q2	nmrd	Changes In Fair Value Of Warrant Liability ChangesInFairValueOfWarrantLiability	-112000	usd
CY2022Q2	nmrd	Changes In Fair Value Of Warrant Liability ChangesInFairValueOfWarrantLiability	-0	usd
CY2023Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-565413	usd
CY2022Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	355329	usd
CY2023Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	596434	usd
CY2022Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	137386	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-69691	usd
CY2022Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-43609	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	583045	usd
CY2022Q2	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	116214	usd
CY2023Q2	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	122569	usd
CY2022Q2	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-120812	usd
CY2023Q2	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
CY2022Q2	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-112279	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2521327	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2384143	usd
CY2023Q2	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
CY2022Q2	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	192114	usd
CY2023Q2	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	-0	usd
CY2022Q2	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	-0	usd
CY2023Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29206	usd
CY2022Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25598	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29206	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-217712	usd
CY2023Q2	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	0	usd
CY2022Q2	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	4700000	usd
CY2023Q2	nmrd	Principal Payments On Note Payable PrincipalPaymentsOnNotePayable	3600000	usd
CY2022Q2	nmrd	Principal Payments On Note Payable PrincipalPaymentsOnNotePayable	4774282	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3600000	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-74282	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-6150533	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2676137	usd
CY2023Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55089	usd
CY2022Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-321263	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10105135	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17749233	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4009691	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14751833	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-2603154	usd
CY2023Q2	nmrd	Net Cash Provided By Used In Operating Activities Continuing Operation NetCashProvidedByUsedInOperatingActivitiesContinuingOperation	2521327	usd
CY2023Q2	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zVhX5kwvVVul" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span style="text-decoration: underline">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. Significant estimates include the assumptions used in the accrual for potential liabilities, the net realizable value of inventory, the valuation of debt and equity instruments, the fair value of derivative liabilities, valuation of stock options issued for services, and deferred tax valuation allowances. Actual results may differ from those estimates.<b> </b></p>
CY2022Q2	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4009691	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10105135	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	2200933	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1586777	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	150353	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	168075	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2351286	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	1754852	usd
CY2023Q2	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6409304	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1175753	shares
CY2023Q2	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84C_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zTYBJfnDfovk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_86C_zXKDJ9TA1QP4"><span style="text-decoration: underline">Reclassification</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In presenting the Company’s condensed consolidated statement of operations for the three months ended June 30, 2022, the Company presented $<span id="xdx_901_ecustom--ChangeInFairValueOfForeignExchangeDerivativeLiability_pp0p0_c20220401__20220630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zQOPz3gjrNvc" title="Change in fair value of foreign exchange derivative liability">839,584 </span>change in fair value of foreign exchange derivative liability as part of General and administrative expense. In presenting the Company’s condensed consolidated statement of operations for the three months ended June 30, 2023, the Company has reclassified the $<span id="xdx_902_ecustom--ChangeInFairValueOfForeignExchangeDerivativeLiability_pp0p0_c20230401__20230630__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherOperatingIncomeExpenseMember_zVdqJAAHPf4j" title="Change in fair value of foreign exchange derivative liability">839,584 </span>to Other income (expense) in the accompanying condensed consolidated statement of operations for the three months ended June 30, 2022. The reclassification had no effect on the previously reported amounts for net loss, cash flows, or net loss per share for the three months ended June 30, 2022, or financial position as of June 30, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p>
CY2023Q1	nmrd	Related Party Transaction Due From To Related Parties RelatedPartyTransactionDueFromToRelatedParties	920780	usd
CY2022Q1	nmrd	Related Party Transaction Due From To Related Parties RelatedPartyTransactionDueFromToRelatedParties	-101297	usd
CY2023Q2	nmrd	Amounts Invoiced By Pharma To Ddl Nm And Tcl Primarily Relating To Research And Development Expenses AmountsInvoicedByPharmaToDdlNmAndTclPrimarilyRelatingToResearchAndDevelopmentExpenses	1514497	usd
CY2022Q2	nmrd	Amounts Invoiced By Pharma To Ddl Nm And Tcl Primarily Relating To Research And Development Expenses AmountsInvoicedByPharmaToDdlNmAndTclPrimarilyRelatingToResearchAndDevelopmentExpenses	949713	usd
CY2023Q2	nmrd	Amounts Repaid By Ddl To Pharma AmountsRepaidByDdlToPharma	2079039	usd
CY2022Q2	nmrd	Amounts Repaid By Ddl To Pharma AmountsRepaidByDdlToPharma	1074796	usd
CY2023Q2	nmrd	Foreign Currency Translation Related Party ForeignCurrencyTranslationRelatedParty	-18503	usd
CY2022Q2	nmrd	Foreign Currency Translation Related Party ForeignCurrencyTranslationRelatedParty	8870	usd
CY2023Q2	nmrd	Related Party Transaction Due From To Related Parties RelatedPartyTransactionDueFromToRelatedParties	337735	usd
CY2022Q2	nmrd	Related Party Transaction Due From To Related Parties RelatedPartyTransactionDueFromToRelatedParties	-217510	usd
CY2023Q1	nmrd	Warrants Issued WarrantsIssued	4796206	shares
CY2023Q1	nmrd	Volatility Interest Rate VolatilityInterestRate	1	pure
CY2022Q1	us-gaap	Derivative Liability Notional Amount DerivativeLiabilityNotionalAmount	6250000	usd
CY2022Q1	nmrd	Fair Value Of Contract Liability Leveraged Amounts FairValueOfContractLiabilityLeveragedAmounts	12500000	usd
CY2022	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	250000	usd
CY2023Q2	us-gaap	Debt Instrument Convertible Terms Of Conversion Feature DebtInstrumentConvertibleTermsOfConversionFeature	On each monthly settlement date, if the USD/GBP spot rate is above $1.359, the Company has the right to convert $250,000 USD into GBP at a fixed rate of $1.359. If the spot rate is between $1.359 and $1.319 on the settlement date, the Company has no obligations, but can convert $250,000 USD into GBP at the spot rate. Finally, if the spot rate is below $1.319 on the monthly settlement date, the Company is obligated to convert $500,000 USD (the settlement date leveraged amount) into GBP at the fixed rate of $1.359. Alternatively, instead of selling $500,000 USD, the Company can pay the difference in the spot rate and the $1.359 exchange rate for $500,000 USD (net settle) to the counterparty.
CY2023Q2	us-gaap	Derivative Liability Notional Amount DerivativeLiabilityNotionalAmount	3500000	usd
CY2023Q1	us-gaap	Derivative Liability Notional Amount DerivativeLiabilityNotionalAmount	4250000	usd
CY2023Q2	nmrd	Fair Value Of Contract Liability Leveraged Amounts FairValueOfContractLiabilityLeveragedAmounts	7000000	usd
CY2023Q1	nmrd	Fair Value Of Contract Liability Leveraged Amounts FairValueOfContractLiabilityLeveragedAmounts	8500000	usd
CY2023Q2	nmrd	Fair Value Of Contract Liabilities Expected Remaining Term FairValueOfContractLiabilitiesExpectedRemainingTerm	P14Y
CY2023	nmrd	Fair Value Of Contract Liabilities Expected Remaining Term FairValueOfContractLiabilitiesExpectedRemainingTerm	P17Y
CY2023Q2	us-gaap	Foreign Currency Contracts Liability Fair Value Disclosure ForeignCurrencyContractsLiabilityFairValueDisclosure	507648	usd
CY2023Q1	us-gaap	Foreign Currency Contracts Liability Fair Value Disclosure ForeignCurrencyContractsLiabilityFairValueDisclosure	731730	usd
CY2023Q2	nmrd	Deposit On Foreign Exchange Contracts DepositOnForeignExchangeContracts	390173	usd
CY2023Q1	nmrd	Deposit On Foreign Exchange Contracts DepositOnForeignExchangeContracts	909666	usd
CY2023Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	17689871	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20797234	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	602708	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	767083	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	17087163	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	20030151	usd
CY2023Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	16967686	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	16942500	usd
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	119477	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3087651	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	767083	usd
CY2023Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	164375	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	602708	usd

Files In Submission

Name	View Source	Status
0001079973-23-001137-index-headers.html	Edgar Link	pending
0001079973-23-001137-index.html	Edgar Link	pending
0001079973-23-001137.txt	Edgar Link	pending
0001079973-23-001137-xbrl.zip	Edgar Link	pending
ex31x1.htm	Edgar Link	pending
ex31x2.htm	Edgar Link	pending
ex32x1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nmra_10q-063023.htm	Edgar Link	pending
nmrd-20230630.xsd	Edgar Link	pending
nmrd-20230630_cal.xml	Edgar Link	unprocessable
nmrd-20230630_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
nmra_10q-063023_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
nmrd-20230630_lab.xml	Edgar Link	unprocessable
nmrd-20230630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NMRD
Nemaura Medical Inc. Stock $nmrd

2023 Q2 Form 10-Q Financial Statement

#000107997323001137 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMRD Nemaura Medical Inc. Stock $nmrd

2023 Q2 Form 10-Q Financial Statement

#000107997323001137 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NMRD
Nemaura Medical Inc. Stock $nmrd